Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX37 in Advanced/Metastatic Solid Tumors and NSCLC
NCT07274813Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX37 in solid tumor (advanced stage), metastatic solid tumor and non-small cell lung cancer (NSCLC), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Dec 2025; status: recruiting.
02
Drugs
HLX37
03
Conditions
solid tumor (advanced stage)metastatic solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07274813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07274813.